hrp0092mte7 | Management of Graves Disease | ESPE2019

Management of Graves' Disease

Cheetham Tim , Lane Laura , Wood Claire

Managing Graves' disease (GD) should be simple. Stop the immune system from targeting the TSH receptor and the disease is cured. Unfortunately this is not yet feasible in most young people and GD is not a trivial condition for those affected. There are significant advantages and disadvantages of all current treatments with no easy way forwards for many and the family's decisions will reflect their perceptions of medical, radiation and surgical risk. The fact that two o...

hrp0092p1-70 | Fetal, Neonatal Endocrinology and Metabolism (to include Hypoglycaemia) | ESPE2019

Congenital Hypothyroidism – Precise Diagnosis with Dual Imaging

Kasongo Laura , Rausin Leon , Nicolescu Ramona

Introduction: Primary congenital hypothyroidism (PCH), defined as thyroid hormone deficiency, can be viewed as an anatomical, clinical, biochemical and radiological spectrum.Its etiology includes thyroid dysgenesis (85%) with defects in thyroid gland development and thyroid dyshormonogenesis (15%) with inborn error of thyroxine synthesis or release.There is growing evidence that precise characterization of ...

hrp0092p3-194 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Coincidental Central Precocious Puberty and Wilms Tumor

Kasongo Laura , Forget Patricia , Nicolescu Ramona

Introduction: Wilms tumor is the most frequent pediatric renal malignancy and its usual presentation is an abdominal mass or hematuria. Unusual presentations have also been reported, such as paraneoplastic syndromes (acquired von Willebrand disease, sudden death due to pulmonary embolism and Cushing syndrome). These conditions can precede, occur concomitantly or present in a later phase of tumor development. Precocious puberty, as paraneoplastic endocrine synd...

hrp0089p3-p077 | Diabetes & Insulin P3 | ESPE2018

Achievement of Therapy Targets in Children and Adolescents with Type 1 Diabetes Mellitus at the ‘Diabetes School’

Tashmanova Akmaral , Danyarova Laura , Rakhimova Gulnara

Aim: The work was initiated to assess efficacy of training and achievement of therapy targets in children and adolescents with type 1 diabetes mellitus in ‘Diabetes Schools’.Method: The five-day training course was conducted in ‘Type 1 Diabetes School’ at the Scientific-Research Institute of Cardiology and Internal Diseases, Kazakhstan Public Health Ministry (Almaty). The training was conducted by means of a structured program contain...

hrp0084s3.2 | Disorders of sex development: An update | ESPE2015

Decision Making in DSD: Development of a Decision Support Tool

Sandberg David , Callens Nina , Siminoff Laura

Background: Disorders/differences of sex development (DSD) differ from other rare conditions which are often accompanied by significant morbidity and mortality. With limited exceptions, DSD are not life-threatening and do not predict a given level of physical health or health-related quality of life across the lifespan. The birth of a child with DSD is anxiety-provoking. Stressors include weathering drawn-out diagnostic testing, difficulty absorbing complex medical information...

hrp0084p1-54 | Diabetes | ESPE2015

‘BestPWS EU’: A Phase 3 Study in Adolescent and Adult Patients With PWS in Europe

Tauber Maithe , Kim Terri , Kreher Nerissa , Kim Dennis , Hauffa Berthold

Background: Prader–Willi Syndrome (PWS) is a complex genetic disease; one hallmark of the disease is failure to regulate hunger and metabolism. Hyperphagia and severe obesity contribute significantly to the morbidity and mortality of this disease. Methionine aminopeptidase 2 (MetAP2) inhibition reduces fat biosynthesis and stimulates fat oxidation and lipolysis. Beloranib is a selective and potent MetAP2 inhibitor. In a 4-week phase 2, placebo-controlled, proof-of-concept...

hrp0084p3-936 | GH & IGF | ESPE2015

Adherence to GH Treatment: Impact of Actual Height, Treatment Duration, and Puberty

Rothermel Juliane , Scheite Karl , Nazari Nadine , Hauffa Berthold , Reinehr Thomas

Background: Adherence to GH treatment is a challenge.Objective and hypotheses: We analysed the impact of treatment duration, treatment success, treatment indication, age, gender, pubertal stage, and height on treatment adherence (TA) to optimise treatment success.Method: Based on the easypod autoinjector used in the Saizen-online prospective, multicenter, open-label, noninterventional study we analyzed TA in 6 months periods. TA wa...

hrp0084p2-301 | Diabetes | ESPE2015

Evaluation of Continuous Glucose Monitoring in Cystic Fibrosis Patients

Bilbao Laura , Clemente Maria , Costas Laura , Gartner Silvia , Losada Milagros , Armengol Eulalia , Yeste Diego , Carrascosa Antonio

Introduction: Use of continuous glucose monitoring (CGM) as a diagnostic tool for cystic fibrosis-related diabetes (CFRD) is receiving increasing attention. We aimed to: i) describe the glucose profile by CGM in CF patients >10 years of age; ii) compare CGM and oral glucose tolerance test (OGTT) results; and iii) evaluate lung function and nutritional status changes over the previous year.Methods: Prospective study of CF patients aged ≥10 years...

hrp0095fc7.5 | Growth and Syndromes | ESPE2022

Population-based assessment of cardiometabolic-related diagnoses in youth with Turner Syndrome: A PEDSnet Study

Davis Shanlee , Furniss Anna , Pyle Laura , Nokoff Natalie

Background: Cardiovascular diseases are the leading cause of premature death among women with Turner syndrome (TS). Studies in youth with TS suggest that cardiometabolic-related dysfunction is present in childhood, however these small convenience samples may not be generalizable to the whole TS population. PEDSnet, the largest pediatric Health Learning System in the United States (US) representing >6 million children, offers a unique opportunity to examine ...

hrp0095p1-311 | Growth and Syndromes | ESPE2022

Variability of the Noonan syndrome phenotypic spectrum in four patients carrying novel LZTR1 gene variants

Meneghin Alice , Mozzato Chiara , Trevisson Eva , Guazzarotti Laura

Noonan syndrome is a genetic condition caused by dysregulation of RAS-MAPK pathway (RASopathy) characterized by great clinical variability and genetic heterogeneity. Many genes has been associated with the disease, including recently LZTR1, which is causative of both dominant and recessive forms. Currently less than one hundred cases of Noonan syndrome has been associated with LZTR1 variants then phenotype related to this gene is poorly known. Here we describ...